Startup Envisia Therapeutics is presenting the results of its ophthalmology research and technology allowing intracameral drug delivery at the Association for Research in Vision and Ophthalmology 2014 annual meeting in Orlando, FL.
Liquidia Technologies launched a new company this week with $25 million in Series A funding aimed at developing an extended-release glaucoma treatment that could last for several months after one injection.
Liquidia Technologies' PRINT platform is a particle-engineering technology that has performed well in two recent studies.
Neal Fowler said a huge market is waiting for nanotech companies; it's just a matter of harnessing the field's potential into practical uses.
Cost is a huge issue in the vaccine industry, especially as companies turn their focus on the developing world. While some groups have looked toward DNA vaccines, virus-like particles (VLPs) and
The Bill and Melinda Gates Foundation, long a staunch supporter of vaccines for children, is putting its money where its mouth is with a $10 million investment in Liquidia Technologies. Xconomy notes
The PATH Malaria Vaccine Initiative (MVI) will have use of Liquidia Technologies' PRINT particle technology for its research into new, more effective malaria vaccines. The technology helps
Chemical & Engineering News has reported on research out of North Carolina into a new class of bioabsorbable materials that can be precisely programmed to degrade by hydrolysis in hours, days,
Liquidia Technologies has garnered the final piece of a $25 million Series C, which will fund development of a new vaccine delivery technology. The clinical research organization PPD invested $5